SILu™Prot IFNG Interferon Gamma human
SIGMA/MSST0039 - recombinant, expressed in HEK 293 cells, SIL MS Protein Standard, 13C and 15N-labeled
Synonym: IFNγ; IFN-gamma; IFNG mass-spectrometry standard; Immune interferon; Immuneinterferon; Interferon-gamma mass-spectrometry standard; stable isotope-labeled human IFNG
Product Type: Chemical
SILuProt products are stable isotope-labeled full length proteins designed to be used as mass spectrometry internal standards for quantitative proteomics. Introduction of an internal SILuProt standard at the beginning of the MS workflow minimizes variations in quantification due to protein extraction, fractionation, enrichment, proteolysis and analysis
| assay | ≥98% (SDS-PAGE) |
| biological source | human |
| form | lyophilized powder |
| mol wt | calculated mol wt 17 kDa |
| potency | ≥98% Heavy amino acids incorporation efficiency by MS |
| Quality Level | 200  |
| recombinant | expressed in HEK 293 cells |
| storage temp. | −20°C |
| suitability | suitable for mass spectrometry (standard) |
| technique(s) | mass spectrometry (MS): suitable |
| UniProt accession no. | P01579  |
| Biochem/physiol Actions: | SILu™Prot IFNG is a recombinant, stable isotope-labeled human IFNG which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of IFNG in mass-spectrometry. SILu Prot IFNG is a homodimer consisting of 138 amino acids, with a calculated molecular mass of 17 kDa. |
| General description: | Interferon gamma (IFNγ) is a dimerized soluble cytokine that is the only member of the type II class of interferons. IFNγ is secreted by T helper cells (specifically, Th1 cells), cytotoxic T cells (TC cells) and Natural killer (NK) cells. When combined with other inflammatory cytokines, evaluating the levels of IFNγ can be used as a diagnostic tool in patients with breast cancer or benign prostatic hyperplasia. A recent study evaluated the effect of a cancer vaccine given to patients with colorectal cancer, on the levels of plasma pro-inflammatory cytokines (including IFN-γ). The study concluded that patients achieving stable disease showed increasing levels of plasma inflammatory cytokines. |
| Immunogen: | QDPYVKEAENLKKYFNAGHSDVADN |
| Legal Information: | SILu is a trademark of Sigma-Aldrich Co. LLC |
| Legal Information: | This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com. |
| Physical form: | Supplied as a lyophilized powder containing phosphate buffered saline. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 23201100 |